Pharmacotherapy of Psychological Disorders Using Psychedelic
Drugs: A Treatise for Psychiatrists

Payal      Ghosh; Debjeet      Sur
Abstract

Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic drugs as Schedule I. The major objective of this review is to highlight the prospective use of specific psychedelic medicines, such as psilocybin, LSD, MDMA, and ayahuasca, in the treatment of various psychiatric conditions, such as treatment-resistant depression, post-traumatic traumatic stress, end-of-life anxiety, and substance misuse disorders. As documented from both animal and human studies, in addition, there will be a study of the effectiveness and safety. The body of research suggests that psychedelics may one day offer revolutionary treatments for mental diseases, contrary to conventional therapy. However, given their distinctive histories and a high potential for abuse with widespread distribution, more care and effort must be given to protect their use as efficient medical treatments instead of drugs of abuse.
[1]
Rossell SL, Meikle SE, Williams ML, Castle DJ. Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? Aust N Z J Psychiatry  2023; 57(7): 935-6.
 [http://dx.doi.org/10.1177/00048674231172691] [PMID:  37139585]

[2]
Hall W, Farrell M. What can we learn from the history of research on psychedelic drugs in the addictions? Addiction  2021; 116(11): 2936-8.
 [http://dx.doi.org/10.1111/add.15560] [PMID:  34382252]

[3]
Siegel AN, Meshkat S, Benitah K, et al. Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res  2021; 139: 71-81.
 [http://dx.doi.org/10.1016/j.jpsychires.2021.05.019] [PMID:  34048997]

[4]
Kaplan RM. Humphry osmond: The psychedelic psychiatrist. IJHSSE  2016; 3: 2349.

[5]
Vollenweider FX, Preller KH. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci  2020; 21(11): 611-24.
 [http://dx.doi.org/10.1038/s41583-020-0367-2] [PMID:  32929261]

[6]
Nutt D. Psychedelic drugs—a new era in psychiatry? Dialogues Clin Neurosci  2019; 21(2): 139-47.
 [http://dx.doi.org/10.31887/DCNS.2019.21.2/dnutt] [PMID:  31636488]

[7]
Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology  2020; 167: 107933.
 [http://dx.doi.org/10.1016/j.neuropharm.2019.107933] [PMID:  31917152]

[8]
Aday JS, Wood JR, Bloesch EK, Davoli CC. Psychedelic drugs and perception: A narrative review of the first era of research. Rev Neurosci  2021; 32(5): 559-71.
 [http://dx.doi.org/10.1515/revneuro-2020-0094] [PMID:  33550787]

[9]
Schenberg EE. Psychedelic drugs as new tools in psychiatric therapeutics. Br J Psychiatry  2021; 43(2): 121-2.
 [http://dx.doi.org/10.1590/1516-4446-2020-0012] [PMID:  32578688]

[10]
Lord LD, Expert P, Atasoy S, et al. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. Neuroimage  2019; 199: 127-42.
 [http://dx.doi.org/10.1016/j.neuroimage.2019.05.060] [PMID:  31132450]

[11]
Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology  2019; 44(7): 1328-34.
 [http://dx.doi.org/10.1038/s41386-019-0324-9] [PMID:  30685771]

[12]
Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol  2020; 13(6): 655-70.
 [http://dx.doi.org/10.1080/17512433.2020.1772054] [PMID:  32478631]

[13]
Krediet E, Bostoen T, Breeksema J, et al. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol  2020; 23(6): 385-400.
 [http://dx.doi.org/10.1093/ijnp/pyaa018]

[14]
Kangaslampi S. Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs. Psychopharmacology  2020; 237(12): 3799-802.
 [http://dx.doi.org/10.1007/s00213-020-05703-9] [PMID:  33151375]

[15]
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res  2020; 284: 112749.
 [http://dx.doi.org/10.1016/j.psychres.2020.112749] [PMID:  31931272]

[16]
Bershad AK, Preller KH, Lee R, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging  2020; 5(4): 461-7.
 [http://dx.doi.org/10.1016/j.bpsc.2019.12.007] [PMID:  32033922]

[17]
Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry  2020; 177(5): 391-410.
 [http://dx.doi.org/10.1176/appi.ajp.2019.19010035] [PMID:  32098487]

[18]
Mitchell JM, Ot’alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nat Med  2023; 29(10): 2473-80.
 [http://dx.doi.org/10.1038/s41591-023-02565-4] [PMID:  37709999]

[19]
González-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron  2007; 53(3): 439-52.
 [http://dx.doi.org/10.1016/j.neuron.2007.01.008] [PMID:  17270739]

[20]
Larkum M. A cellular mechanism for cortical associations: An organizing principle for the cerebral cortex. Trends Neurosci  2013; 36(3): 141-51.
 [http://dx.doi.org/10.1016/j.tins.2012.11.006] [PMID:  23273272]

[21]
Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry  2011; 68(1): 71-8.
 [http://dx.doi.org/10.1001/archgenpsychiatry.2010.116] [PMID:  20819978]

[22]
Doblin RE, Christiansen M, Jerome L, Burge B. The past and future of psychedelic science: An introduction to this issue. J Psychoactive Drugs  2019; 51(2): 93-7.
 [http://dx.doi.org/10.1080/02791072.2019.1606472] [PMID:  31132970]

[23]
Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med  2019; 49(4): 655-63.
 [http://dx.doi.org/10.1017/S0033291718001356] [PMID:  29903051]

[24]
Winter JC, Rice KC, Amorosi DJ, Rabin RA. Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav  2007; 87(4): 472-80.
 [http://dx.doi.org/10.1016/j.pbb.2007.06.003] [PMID:  17688928]

[25]
Carbonaro TM, Bradstreet MP, Barrett FS. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol  2016; 30(12): 1268-78.

[26]
Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol  2019; 33(9): 1076-87.
 [http://dx.doi.org/10.1177/0269881119855974] [PMID:  31294673]

[27]
Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage  2017; 159: 70-8.
 [http://dx.doi.org/10.1016/j.neuroimage.2017.07.020] [PMID:  28711736]

[28]
Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep  2018; 23(11): 3170-82.
 [http://dx.doi.org/10.1016/j.celrep.2018.05.022] [PMID:  29898390]

[29]
Calvey T, Howells FM. An introduction to psychedelic neuroscience. In: Progress in Brain Research.  Elsevier B.V. 2018; pp. 1-23.
 [http://dx.doi.org/10.1016/bs.pbr.2018.09.013]

[30]
Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskr Nor Laegeforen  2018; 138(18)
 [http://dx.doi.org/10.4045/tidsskr.17.1110]

[31]
Sellers EM, Romach MK, Leiderman DB. Studies with psychedelic drugs in human volunteers. Neuropharmacology  2018; 142: 116-34.
 [http://dx.doi.org/10.1016/j.neuropharm.2017.11.029] [PMID:  29162429]

[32]
Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: A pharmacological fMRI study. J Neurosci  2018; 38(14): 3603-11.
 [http://dx.doi.org/10.1523/JNEUROSCI.1939-17.2018] [PMID:  29555857]

[33]
Stroud JB, Freeman TP, Leech R, et al. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology  2018; 235(2): 459-66.
 [http://dx.doi.org/10.1007/s00213-017-4754-y] [PMID:  29085980]

[34]
Lladó-Pelfort L, Celada P, Riga MS. Effects of hallucinogens on neuronal activity.In: Current Topics in Behavioral Neurosciences.  Springer Verlag 2018; pp. 75-105.

[35]
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology  2017; 42(11): 2105-13.
 [http://dx.doi.org/10.1038/npp.2017.84] [PMID:  28443617]

[36]
Evans JW, Szczepanik J, Brutsché N, Park LT, Nugent AC, Zarate CA Jr. Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. Biol Psychiatry  2018; 84(8): 582-90.
 [http://dx.doi.org/10.1016/j.biopsych.2018.01.027] [PMID:  29580569]

[37]
Marek GJ. Interactions of hallucinogens with the glutamatergic system: Permissive network effects mediated through cortical layer V pyramidal neuronsCurrent Topics in Behavioral Neurosciences.  Springer Verlag 2018; pp. 107-35.

[38]
Preller KH, Herdener M, Pokorny T, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol  2017; 27(3): 451-7.
 [http://dx.doi.org/10.1016/j.cub.2016.12.030] [PMID:  28132813]

[39]
Kraehenmann R, Pokorny D, Vollenweider L, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology  2017; 234(13): 2031-46.
 [http://dx.doi.org/10.1007/s00213-017-4610-0] [PMID:  28386699]

[40]
Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic drugs in biomedicine. Trends Pharmacol Sci  2017; 38(11): 992-1005.
 [http://dx.doi.org/10.1016/j.tips.2017.08.003] [PMID:  28947075]

[41]
Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol  2016; 30(12): 1165-80.
 [http://dx.doi.org/10.1177/0269881116675512] [PMID:  27909164]

[42]
Rucker JJH, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: A systematic review. J Psychopharmacol  2016; 30(12): 1220-9.
 [http://dx.doi.org/10.1177/0269881116679368] [PMID:  27856684]

[43]
Barre A, Berthoux C, De Bundel D, et al. Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning. Proc Natl Acad Sci  2016; 113(10): E1382-91.
 [http://dx.doi.org/10.1073/pnas.1525586113] [PMID:  26903620]

[44]
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol  2015; 29(3): 289-99.
 [http://dx.doi.org/10.1177/0269881114565144] [PMID:  25586396]

[45]
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol  2014; 28(11): 983-92.
 [http://dx.doi.org/10.1177/0269881114548296] [PMID:  25213996]

[46]
Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol  2016; 26(4): 756-66.
 [http://dx.doi.org/10.1016/j.euroneuro.2016.01.005] [PMID:  26875114]

[47]
Lebedev AV, Lövdén M, Rosenthal G. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp  2015; 36: 3137-53.

[48]
Osório FL, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev Bras Psiquiatr  2015; 37(1): 13-20.
 [http://dx.doi.org/10.1590/1516-4446-2014-1496] [PMID:  25806551]

[49]
Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol  2012; 26(7): 994-1002.
 [http://dx.doi.org/10.1177/0269881112439253] [PMID:  22406913]

[50]
Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J Psychopharmacol  2015; 29(1): 57-68.
 [http://dx.doi.org/10.1177/0269881114555249] [PMID:  25389218]

[51]
Belouin SJ, Henningfield JE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology  2018; 142: 7-19.
 [http://dx.doi.org/10.1016/j.neuropharm.2018.02.018] [PMID:  29476779]

[52]
Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. Front Integr Nuerosci  2013; 7: 25. Epub ahead of print
 [http://dx.doi.org/10.3389/fnint.2013.00025] [PMID:  23626526]

[53]
Wood J, Kim Y, Moghaddam B. Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. J Neurosci  2012; 32(9): 3022-31.
 [http://dx.doi.org/10.1523/JNEUROSCI.6377-11.2012] [PMID:  22378875]

[54]
Saulin A, Savli M, Lanzenberger R. Serotonin and molecular neuroimaging in humans using PET. Amino Acids  2012; 42(6): 2039-57.
 [http://dx.doi.org/10.1007/s00726-011-1078-9] [PMID:  21947614]

[55]
Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology  2012; 37(3): 630-40.
 [http://dx.doi.org/10.1038/npp.2011.228] [PMID:  21956447]

[56]
McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov  2022; 21(6): 463-73.
 [http://dx.doi.org/10.1038/s41573-022-00421-7] [PMID:  35301459]

[57]
Vollenweider FX, Smallridge JW. Classic psychedelic drugs: Update on biological mechanisms. Pharmacopsychiatry  2022; 55(3): 121-38.
 [http://dx.doi.org/10.1055/a-1721-2914] [PMID:  35079988]

[58]
Benneyworth MA, Smith RL, Barrett RJ, Sanders-Bush E. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice. Psychopharmacology  2005; 179(4): 854-62.
 [http://dx.doi.org/10.1007/s00213-004-2108-z] [PMID:  15645221]

[59]
Bolwig TG. Neuroimaging and electroconvulsive therapy: A review. J ECT  2014; 30(2): 138-42.
 [http://dx.doi.org/10.1097/YCT.0000000000000140] [PMID:  24800687]

[60]
Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci  2012; 109(6): 2138-43.
 [http://dx.doi.org/10.1073/pnas.1119598109] [PMID:  22308440]

[61]
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol  2011; 25(4): 439-52.
 [http://dx.doi.org/10.1177/0269881110378371] [PMID:  20643699]

[62]
McAlonan K, Cavanaugh J, Wurtz RH. Guarding the gateway to cortex with attention in visual thalamus. Nature  2008; 456(7220): 391-4.
 [http://dx.doi.org/10.1038/nature07382] [PMID:  18849967]

[63]
Santos RG, Bouso JC, Hallak JEC. Ayahuasca: What mental health professionals need to know. Arch Clin Psychiatry  2017; 44(4): 103-9.
 [http://dx.doi.org/10.1590/0101-60830000000130]

[64]
de Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. J Neurosci  2021; 41(5): 891-900.
 [http://dx.doi.org/10.1523/JNEUROSCI.1659-20.2020]

[65]
Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry  2018; 23(4): 801-11.
 [http://dx.doi.org/10.1038/mp.2017.255] [PMID:  29532791]

[66]
Villanueva V, Garcés M, López-González FJ, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res  2016; 126: 201-10.
 [http://dx.doi.org/10.1016/j.eplepsyres.2016.08.001] [PMID:  27521586]

[67]
Greicius MD, Flores BH, Menon V, et al. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry  2007; 62(5): 429-37.
 [http://dx.doi.org/10.1016/j.biopsych.2006.09.020] [PMID:  17210143]
Cite As
Current Psychiatry Research and Reviews

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Abstract
